Trial of fibrate therapy in primary biliary cholangitis shows treatment is well tolerated

(European Association for the Study of the Liver) The results of the BEZURSO study, found that bezafibrate in combination with UDCA normalized prognostic markers of liver disease in patients with PBC with an inadequate response to UDCA. The study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that the bezafibrate and UDCA combination therapy was well tolerated, normalized prognostic biochemical parameters, improved fatigue and itching, and prevented progression of liver stiffness and ELF score, which are predictors of liver failure and mortality.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2q12gIF